Boston scientific receives fda approval for expanded labeling of watchman flx™ laac device for dual anti-platelet therapy as post-procedural medication option

Watchman flx now the only laac technology in the united states that allows for either dapt or oac immediately following implantation marlborough, mass. , sept. 6, 2022 /prnewswire/ -- boston scientific corporation (nyse: bsx) has received u.s. food and drug administration (fda) approval to expand the instructions for use labeling for the current-generation watchman flx™ left atrial appendage closure (laac) device to include a 45-day dual anti-platelet therapy (dapt) option as an alternative to 45-day oral anticoagulation (oac) plus aspirin for post-procedural treatment of patients with non-valvular atrial fibrillation (nvaf).
BSX Ratings Summary
BSX Quant Ranking